Sørensen K V, Christensen S E, Dupont E, Hansen A P, Pedersen E, Orskov H
Acta Neurol Scand. 1980 Mar;61(3):186-91. doi: 10.1111/j.1600-0404.1980.tb01481.x.
In 27 patients with multiple sclerosis (MS), and in 10 control subjects of comparable age, percent ideal body weight and sex ratio, the cerebrospinal fluid (CSF) content of somatostatin was measured by radioimmunoassay. The results showed that the group of patients in relapse (n = 16) had significantly lower somatostatin content in CSF (95 +/- 4.1 (SEM) pg/ml) than both the control group (142 +/- 8.4 pg/ml) and the group of MS patients (n = 11), who had been in a clinical stable phase for more than 6 months (131 +/- 3.2 pg/ml). Duration of the disease and degree of neurological impairment were apparently without relation to the reduction of somatostatin content in the CSF. There was no relationship between CSF content of somatostatin and the content of total protein or IgG, neither of which showed any relationship to the activity of the disease.
对27例多发性硬化症(MS)患者以及10名年龄、理想体重百分比和性别比例相当的对照者,采用放射免疫分析法测定其脑脊液(CSF)中生长抑素的含量。结果显示,复发组患者(n = 16)脑脊液中生长抑素含量(95±4.1(SEM)pg/ml)显著低于对照组(142±8.4 pg/ml)以及临床稳定期超过6个月的MS患者组(n = 11,131±3.2 pg/ml)。病程和神经功能损害程度显然与脑脊液中生长抑素含量的降低无关。脑脊液中生长抑素含量与总蛋白或IgG含量之间无相关性,且二者均与疾病活动度无关。